Immunization Analysis and Insights
The Immunization Analysis & Insights Unit is a data hub and analytics engine for immunization data and performs analytics. The unit supports the work of other technical units within the department of Immunization, Vaccines and Biologicals (IVB) and drives innovation in data quality and use in countries. It also has responsibility for IVB’s global work on VPD surveillance and generating data and evidence on the public health and economic impact of vaccines.

Full Value of improved Influenza Vaccine Assessment (FVIVA)

Objective:The Full Value of improved influenza vaccine assessment (FVIVA) aims to inform global efforts to expand seasonal influenza programs as part of a larger pandemic readiness effort and to drive innovative research for next-generation influenza vaccines for LMICs.


A monk receives a vaccine

Methodology:

The project is divided into 4 workstreams:

  • Workstream 1 collects, synthesizes, and documents current seasonal and improved influenza vaccine development (including pipeline, and innovation assessments), and supply-related evidence (including current manufacturing, and influenza vaccine supply drivers and barriers)
  • Workstream 2 estimates the potential market demand and willingness to pay for current seasonal and improved influenza vaccines
  • Workstream 3 measures and quantifies the incremental health and economic impact of improved seasonal influenza vaccines, based on their characteristics, compared to current seasonal influenza vaccines.
  • Workstream 4 assesses the market conditions necessary for sustainable development and supply of next generation vaccines through price benchmarking and discounted cashflow analyses and also reviews the lessons learned from existing seasonal influenza vaccine programs and their implications for future access to improved influenza vaccines.

Timeline: The project started in 2023 and is expected to be completed by the end of 2025.

FVIVA Technical Advisory Group members:

  • Jon Abramson
  • Salah Al Awaidy
  • Edwine Barasa
  • Silvia Bino
  • Rebecca Cox
  • Luzhao Feng
  • Jodie McVernon
  • Harish Nair
  • Anthony Newall
  • Punnee Pitisuttithum
  • Diane Post
  • Cecile Vibound

Partners: U.S. Centers for Disease Control and Prevention, The Task Force for Global Health, Bill and Melinda Gates Foundation, and London School of Hygiene Tropical Medicine

Advice of the WHO Immunization and vaccines related implementation research advisory committee

12 – 16 September 2022

Immunization and vaccines related implementation research advisory committee (IVIR-AC) - September 2022
1 – 5 March 2021

Immunization and vaccines related implementation research advisory committee (IVIR-AC) - March 2021

 

Related Publications

Influenza Preferred Product Characteristics (expected in Q1 2025) 

Bresee J, Koh M, Chadwick C, Jit M, Soble A, Lambach P. The need and ongoing efforts to understand the full value of improved influenza vaccines. Vaccine. 2023;41(48):7044-7046. doi:10.1016/j.vaccine.2023.10.047

Waterlow NR, Procter SR, van Leeuwen E, Radhakrishnan S, Jit M, Eggo RM. The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis. Vaccine. 2023;41(41):6017-6024. doi:10.1016/j.vaccine.2023.08.031

Waterlow NR, Radhakrishnan S, Dawa J, et al. Potential health and economic impact of paediatric vaccination using next-generation influenza vaccines in Kenya: a modelling study. BMC Med. 2023;21(1):106. Published 2023 Mar 22. doi:10.1186/s12916-023-02830-w

Trotter C, Giersing B, Lindstrand A, et al. A Practical Guide to Full Value of Vaccine Assessments. Vaccines (Basel). 2024;12(2):201. Published 2024 Feb 16. doi:10.3390/vaccines12020201